pdlim7 Antibody

What is PDLIM7 and why is it important in research?

PDLIM7 (PDZ and LIM domain 7) is a 457 amino acid protein with a mass of 49.8 kDa that functions primarily as a scaffold protein facilitating coordinated protein assembly. It has notable expression in heart and skeletal muscle tissues, with subcellular localization in the cytoplasm . PDLIM7 is increasingly studied due to its involvement in bone formation mechanisms, BMP6 signaling pathways, and its overexpression in certain cancers like thyroid cancer . The protein is also known by several synonyms including LMP3, LIM domain protein, LMP, and LMP1, which researchers should be aware of when reviewing literature .

What are the key considerations when selecting a PDLIM7 antibody for experimental applications?

When selecting a PDLIM7 antibody, researchers should consider:

• Application compatibility: Different antibodies are optimized for specific applications. According to available product data, antibodies should be selected based on their validated performance in Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC), Immunocytochemistry (ICC), or Flow Cytometry (FCM) .

• Species reactivity: Confirm the antibody reacts with your species of interest. Available antibodies show reactivity with human, mouse, and rat PDLIM7 .

• Recognized epitope: Some antibodies target specific regions, such as the "middle region" of PDLIM7, which may be important depending on which protein domain or isoform you're studying .

• Validation data: Review available citations and figures demonstrating the antibody's performance in published research .

• Isoform recognition: Since PDLIM7 has up to 6 reported isoforms, verify which isoforms your selected antibody can detect .

What are the established experimental controls when working with PDLIM7 antibodies?

Proper experimental controls for PDLIM7 antibody research should include:

• Positive tissue controls: Heart and skeletal muscle tissues show notable PDLIM7 expression and serve as effective positive controls .

• Negative controls: Use tissues or cell lines with minimal PDLIM7 expression, or employ isotype controls matching the primary antibody's host species.

• Knockdown/knockout validation: For definitive specificity confirmation, compare antibody staining between wild-type samples and those with PDLIM7 knockdown/knockout.

• Loading controls: For Western blot applications, use housekeeping proteins (β-actin, GAPDH) to normalize protein loading.

• Concentration gradients: Test antibody performance across various concentrations to determine optimal signal-to-noise ratio, as exemplified in the published Western blot data showing clear PDLIM7 detection at 0.04 μg/mL concentration .

How should PDLIM7 antibodies be optimized for Western blot applications?

For optimal Western blot results with PDLIM7 antibodies:

• Protein loading: Published protocols successfully detect PDLIM7 using 15-50 μg of whole cell lysate, with clear band visualization at both concentrations .

• Antibody dilution: Start with manufacturer-recommended dilutions, typically around 0.04 μg/mL for PDLIM7 antibodies as demonstrated in published research .

• Membrane optimization: PVDF membranes are generally preferred for detecting proteins in the 50 kDa range like PDLIM7.

• Detection method selection: Both chemiluminescence and fluorescence-based detection systems work well, with selection depending on required sensitivity and dynamic range.

• Blocking optimization: Use 5% non-fat dry milk or BSA in TBST, optimizing blocking time to minimize background while maintaining specific signal.

• Expected band patterns: Anticipate the canonical PDLIM7 band at approximately 49.8 kDa, but be prepared for additional bands representing the various isoforms (up to 6) that have been reported .

What are the recommended protocols for immunohistochemistry applications with PDLIM7 antibodies?

For successful immunohistochemistry using PDLIM7 antibodies:

• Fixation method: 10% neutral buffered formalin fixation is generally compatible with most PDLIM7 antibodies validated for IHC-p (paraffin sections) .

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) is typically effective for PDLIM7 detection.

• Blocking strategy: Block with 5-10% normal serum from the same species as the secondary antibody for 1 hour at room temperature.

• Primary antibody incubation: Incubate with PDLIM7 antibody at manufacturer-recommended dilutions, typically overnight at 4°C.

• Detection systems: Both DAB (3,3'-diaminobenzidine) and fluorescent secondary antibodies have been successfully used with PDLIM7 antibodies .

• Controls: Include known positive tissues (heart/skeletal muscle) and negative controls (primary antibody omission) in each experiment .

• Counterstaining: Light hematoxylin counterstaining helps visualize tissue architecture without obscuring specific PDLIM7 staining.

How can immunoprecipitation be optimized for studying PDLIM7 protein interactions?

To optimize immunoprecipitation for PDLIM7 interaction studies:

• Antibody selection: Use antibodies specifically validated for IP applications, such as those indicated in the product data .

• Lysis buffer optimization: Use buffers that preserve protein-protein interactions while effectively extracting PDLIM7 (typically RIPA or NP-40 based buffers with protease inhibitors).

• Pre-clearing strategy: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody amounts: Typically 2-5 μg of antibody per 500 μg of protein lysate provides good results for PDLIM7 immunoprecipitation.

• Washing stringency: Optimize wash buffer composition to remove non-specific interactions while preserving genuine PDLIM7 binding partners.

• Elution methods: Use either acidic elution or direct boiling in sample buffer depending on downstream applications.

• Interaction verification: Confirm interactions through reverse IP (immunoprecipitating the suspected binding partner and blotting for PDLIM7), as demonstrated in studies of PDLIM7 interactions with PI3K/AKT, MDM2, and BMP-1 proteins .

How is PDLIM7 expression altered in thyroid cancer, and what experimental approaches best characterize these changes?

PDLIM7 (Enigma protein) shows stage-dependent overexpression in thyroid cancer, suggesting involvement in cancer initiation and progression . To characterize these expression changes:

• Protein expression analysis: Western blotting with densitometric analysis shows differential upregulation of Enigma protein across various papillary thyroid carcinoma (PTC) stages compared to benign tissues .

• Transcriptional analysis: RT-qPCR assays can quantify PDLIM7 mRNA levels, with studies showing variable expression patterns in thyroid cancer samples .

• Correlation with staging: Statistical analyses including Pearson's correlation can establish relationships between PDLIM7 expression and cancer staging, though current data shows modest correlation coefficients (r = 0.17866, p = 0.0978) as indicated in the following table:

• Immunohistochemical mapping: IHC using validated PDLIM7 antibodies allows visualization of protein expression patterns within tumor microenvironments .

• Comparative analysis: Compare expression across different thyroid cancer subtypes and stages to establish PDLIM7 as a potential biomarker .

What are the key PDLIM7 protein interactions in cancer pathways, and how can they be experimentally validated?

PDLIM7 interacts with several critical cancer-related signaling pathways, particularly in thyroid cancer . These interactions and their experimental validation methods include:

• PI3K/AKT pathway interaction:

  • Detection method: Co-immunoprecipitation followed by Western blot analysis

  • Significance: Strong interactions observed between PDLIM7 and PI3K/AKT, suggesting involvement in proliferation and survival signaling

  • Validation approach: Both forward and reverse IP confirm this interaction

• MDM2 interaction:

  • Detection method: Immunoprecipitation and reverse IP

  • Significance: Strong binding observed, potentially affecting p53 pathway regulation

  • Controls: Non-specific IgG precipitations serve as negative controls

• BMP-1 interaction:

  • Detection method: Co-IP techniques

  • Significance: Weaker interaction detected, potentially linked to PDLIM7's role in bone formation pathways

  • Analysis: Western blot quantification determines relative interaction strengths

• VDR pathway connections:

  • Detection: Differential expression analysis alongside PDLIM7

  • Experimental approach: Monitor expression of both proteins across cancer progression

• DBP association:

  • Observation: Loss of DBP correlates with increased PDLIM7 expression in some PTC subsets

  • Validation method: Paired expression analysis in matched samples

What is the relationship between PDLIM7 and microRNA regulation in cancer, and how can this be studied?

PDLIM7 expression appears to be regulated by microRNAs, particularly the Let-7 family, in thyroid cancer contexts . To study this relationship:

• Expression correlation analysis: Perform RT-qPCR for both PDLIM7 and target miRNAs (particularly let-7g) in the same tissue samples. Current data shows a significant but weak inverse correlation (r = -0.27, p < 0.05) between PDLIM7 and let-7g expression .

• In vitro manipulation: Conduct miRNA mimic or inhibitor transfection experiments to directly test the effect of specific miRNAs on PDLIM7 expression.

• Luciferase reporter assays: Construct reporters containing PDLIM7 3'UTR to confirm direct binding of candidate miRNAs.

• Western blot validation: Confirm that changes in miRNA levels correspond to changes in PDLIM7 protein expression.

• Functional rescue experiments: Determine if restoring miRNA levels can normalize PDLIM7 expression and associated phenotypes in cancer models.

• Pathway integration analysis: Investigate how miRNA regulation of PDLIM7 affects downstream signaling pathways (PI3K/AKT, MDM2) in cancer contexts .

What are common sources of non-specific binding with PDLIM7 antibodies, and how can they be mitigated?

Non-specific binding can compromise PDLIM7 antibody experiments. Common issues and solutions include:

• Multiple bands in Western blots:

  • Potential cause: Detection of multiple PDLIM7 isoforms (up to 6 reported)

  • Solution: Verify band patterns against predicted molecular weights of known isoforms; use positive controls with known expression patterns

  • Validation: Compare results with knockout/knockdown samples

• Background in immunohistochemistry:

  • Optimization: Increase blocking duration (5% BSA or normal serum) and optimize antibody concentration

  • Technical approach: Add 0.1-0.3% Triton X-100 for better antibody penetration

  • Controls: Include isotype control antibodies at matching concentrations

• Cross-reactivity with related proteins:

  • Issue: The PDZ and LIM domain family has multiple members with structural similarities

  • Solution: Select antibodies raised against unique epitopes of PDLIM7

  • Verification: Test antibody specificity across multiple applications (WB, IHC, IP)

• Lot-to-lot variability:

  • Challenge: Inconsistent results between antibody lots

  • Approach: Document lot numbers and validate each new lot against previous results

  • Solution: Consider recombinant antibodies for better consistency

How can researchers troubleshoot inconsistent PDLIM7 detection across different experimental systems?

When facing inconsistent PDLIM7 detection:

• Sample preparation optimization:

  • For protein extraction: Test different lysis buffers (RIPA vs. NP-40) to optimize PDLIM7 solubilization

  • For tissue samples: Standardize fixation times and processing methods

  • For cell lines: Consider cell density and culture conditions that might affect PDLIM7 expression

• Antibody validation across systems:

  • Test multiple validated antibodies targeting different epitopes

  • Verify antibody performance in your specific model system before extensive experiments

  • Consider using pooled antibodies for improved detection of challenging samples

• Expression level considerations:

  • Adjust exposure times and antibody concentrations based on expected expression levels

  • For low-expressing samples, consider signal amplification methods

  • Use positive controls (heart/skeletal muscle) with known high PDLIM7 expression

• Technical parameters:

  • For Western blots: Optimize transfer conditions for the 50 kDa range

  • For IHC: Test multiple antigen retrieval methods (heat vs. enzymatic)

  • For immunofluorescence: Adjust fixation methods to preserve epitope structure

What are the best strategies for quantifying PDLIM7 expression changes in experimental models?

For accurate PDLIM7 quantification:

• Western blot densitometry:

  • Use appropriate normalization to housekeeping proteins

  • Employ graduated loading series to ensure linearity of signal

  • Utilize software like ImageJ for standardized analysis

  • Example: Published Western blots show clear quantifiable bands at 0.04 μg/mL antibody concentration

• qPCR optimization:

  • Design primers spanning exon junctions to avoid genomic DNA amplification

  • Validate primers with efficiency curves and melt curve analysis

  • Use multiple reference genes for normalization

  • Calculate using comparative Ct (2^-ΔΔCt) method as demonstrated in thyroid cancer studies

• Immunohistochemistry quantification:

  • Implement digital pathology approaches with consistent thresholding

  • Use H-score or Allred scoring systems for semi-quantitative analysis

  • Apply automated image analysis to minimize subjectivity

  • Include calibration samples in each experimental batch

• Flow cytometry:

  • Optimize permeabilization for this cytoplasmic target

  • Use median fluorescence intensity for quantification

  • Include fluorescence minus one (FMO) controls

  • Consider dual staining to normalize for cell size/complexity

How can PDLIM7 antibodies be used to investigate protein-protein interactions beyond conventional co-immunoprecipitation?

Advanced techniques for studying PDLIM7 interactions include:

• Proximity ligation assay (PLA):

  • Methodology: Use pairs of antibodies (anti-PDLIM7 and anti-interacting protein) with oligonucleotide-conjugated secondary antibodies

  • Advantage: Visualize interactions in situ with subcellular resolution

  • Application: Map PDLIM7 interactions with PI3K/AKT, MDM2, and BMP-1 within specific cellular compartments

• FRET/BRET analysis:

  • Approach: Tag PDLIM7 and candidate interactors with compatible fluorophores/bioluminescent proteins

  • Benefit: Real-time monitoring of dynamic interactions in living cells

  • Experimental design: Create tagged constructs preserving the PDZ and LIM domains critical for PDLIM7 functions

• BioID or APEX proximity labeling:

  • Method: Fuse PDLIM7 with biotin ligase to biotinylate nearby proteins

  • Advantage: Identifies weak or transient interactions missed by conventional IP

  • Analysis: Mass spectrometry of biotinylated proteins reveals the PDLIM7 interactome

• Crosslinking mass spectrometry:

  • Technique: Apply protein crosslinkers followed by MS analysis

  • Benefit: Provides structural information about interaction interfaces

  • Application: Map specific domains involved in PDLIM7's scaffold functions

• Co-localization microscopy:

  • Approach: Multiple-label immunofluorescence with validated PDLIM7 antibodies

  • Resolution enhancement: Super-resolution techniques (STORM, PALM) for nanoscale interaction mapping

  • Quantification: Use Pearson's or Mander's coefficients for objective co-localization analysis

What are emerging applications of PDLIM7 antibodies in biomarker development for cancer diagnostics?

Emerging PDLIM7 biomarker applications include:

• Stage-specific expression patterns:

  • Research finding: PDLIM7 shows stage-dependent overexpression in thyroid cancer

  • Diagnostic application: Potential stratification marker for cancer progression

  • Implementation: Standardized IHC scoring systems for clinical pathology

• Integrated multi-marker panels:

  • Approach: Combine PDLIM7 with other markers (e.g., VDR, DBP) for improved diagnostic accuracy

  • Statistical validation: Multivariate analysis to determine optimal marker combinations

  • Clinical potential: Enhanced sensitivity/specificity over single-marker approaches

• Liquid biopsy development:

  • Methodology: Detection of circulating PDLIM7 protein or PDLIM7-expressing exosomes

  • Advantage: Non-invasive monitoring of cancer progression

  • Technique: Highly sensitive immunoassays optimized for serum/plasma samples

• Predictive biomarker potential:

  • Investigation focus: Correlation between PDLIM7 expression and treatment responses

  • Research approach: Retrospective and prospective analysis of treatment outcomes

  • Application: Patient stratification for personalized medicine approaches

• miRNA-PDLIM7 paired biomarkers:

  • Rationale: Inverse correlation between let-7g and PDLIM7 expression in thyroid cancer

  • Methodology: Simultaneous quantification of let-7g miRNA and PDLIM7 protein

  • Diagnostic value: Potentially higher specificity than either marker alone

How might CRISPR-based approaches enhance the understanding of PDLIM7 function when combined with antibody-based detection methods?

Integrating CRISPR and antibody-based methods offers powerful approaches:

• Domain-specific functional mapping:

  • CRISPR approach: Generate precise deletions of PDZ or LIM domains

  • Antibody application: Use domain-specific antibodies to confirm deletions

  • Functional analysis: Map which domains mediate specific protein interactions (PI3K/AKT, MDM2, BMP-1)

• Isoform-specific knockouts:

  • CRISPR strategy: Target specific exons to eliminate individual PDLIM7 isoforms

  • Antibody validation: Confirm isoform elimination using isoform-specific antibodies

  • Functional differentiation: Determine unique roles of the reported 6 PDLIM7 isoforms

• Endogenous tagging for live-cell imaging:

  • Genome editing: Insert fluorescent protein tags or epitope tags at the PDLIM7 locus

  • Validation: Compare tagged protein localization with antibody staining patterns

  • Application: Real-time tracking of PDLIM7 during cellular processes

• CRISPRi for graded expression modulation:

  • Approach: Use dCas9-based transcriptional repression to titrate PDLIM7 levels

  • Quantification: Antibody-based detection methods to measure expression reduction

  • Analysis: Dose-response relationships between PDLIM7 levels and phenotypes

• Compensatory mechanism investigation:

  • CRISPR strategy: Generate PDLIM7 knockout cell lines/organisms

  • Antibody application: Screen for changes in related PDZ/LIM family proteins

  • Interpretation: Identify adaptive responses that may explain conflicting experimental results